Journal article
Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis
KA Patterson, PJ Roberts-Thomson, S Lester, JA Tan, P Hakendorf, M Rischmueller, J Zochling, J Sahhar, P Nash, J Roddy, C Hill, M Nikpour, W Stevens, SM Proudman, JG Walker
Arthritis and Rheumatology | Published : 2015
DOI: 10.1002/art.39316
Abstract
Objective To determine the relationships between systemic sclerosis (SSc)-related autoantibodies, as well as their clinical associations, in a well-characterized Australian patient cohort. Methods Serum from 505 Australian SSc patients were analyzed with a commercial line immunoassay (EuroLine; Euroimmun) for autoantibodies to centromere proteins CENP-A and CENP-B, RNA polymerase III (RNAP III; epitopes 11 and 155), the 90-kd nucleolar protein NOR-90, fibrillarin, Th/To, PM/Scl-75, PM/Scl-100, Ku, topoisomerase I (topo I), tripartite motif-containing protein 21/Ro 52, and platelet-derived growth factor receptor. Patient subgroups were identified by hierarchical clustering of the first 2 dime..
View full abstractGrants
Funding Acknowledgements
Supported by a donation from Euroimmun (Lubeck, Germany) for the line immunoblot instrument, SSc profile kits, and flatbed scanner. The SSc patients were recruited as part of the Australian Scleroderma Cohort Study, which is managed by the Australian Scleroderma Interest Group and is supported by St. Vincent's Hospital IT Department and Research Endowment Foundation, Scleroderma Australia, Arthritis Australia, and unrestricted educational grants from Actelion Australia, GlaxoSmithKline, and Pfizer.